PRESS RELEASE published on 10/20/2025 at 13:30, 11 months 6 days ago Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program Sanofi's Tzield accepted for expedited review by FDA under National Priority Voucher pilot program to delay progression of stage 3 type 1 diabetes. Breakthrough therapy with significant unmet medical need addressed FDA Sanofi Type 1 Diabetes Tzield National Priority Voucher
PRESS RELEASE published on 10/20/2025 at 13:30, 11 months 6 days ago Communiqué de presse : L’autorisation de Sanofi pour Tzield a été acceptée aux États-Unis pour le diabète de type 1 de stade 3 dans le cadre du programme pilote du voucher national de priorité du Commissaire de la FDA La FDA accepte l'examen de Tzield pour le diabète de type 1 de stade 3 aux États-Unis dans le cadre du programme piloté du voucher national de priorité du Commissaire, offrant un potentiel de traitement novateur FDA Autorisation Diabète De Type 1 Tzield Traitement Novateur
BRIEF published on 10/20/2025 at 08:35, 11 months 6 days ago Sanofi's AlphaMedix Shows Promise in Treating GEP-NETs Phase 2 Study Sanofi AlphaMedix GEP-NETs Targeted Alpha Therapy
BRIEF published on 10/20/2025 at 08:35, 11 months 6 days ago AlphaMedix de Sanofi se révèle prometteur dans le traitement des TNE-GEP Étude De Phase 2 Sanofi AlphaMedix GEP-NET Thérapie Alpha Ciblée
PRESS RELEASE published on 10/20/2025 at 08:30, 11 months 6 days ago Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...) Les nouvelles données de l'essai de phase 2 ALPHAMEDIX-02 soulignent le potentiel thérapeutique prometteur d'AlphaMedix™ pour les tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP), avec des réponses prolongées et significatives chez les patients Essai De Phase 2 AlphaMedix Potentiel Thérapeutique TNE-GEP Alphathérapie
PRESS RELEASE published on 10/20/2025 at 08:30, 11 months 6 days ago Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New phase 2 data presented at ESMO Congress highlight AlphaMedix as a promising targeted alpha therapy for GEP-NETs, showing high response rates and potential to address unmet medical needs ESMO Congress AlphaMedix Phase 2 Data GEP-NETs Targeted Alpha Therapy
BRIEF published on 10/20/2025 at 07:05, 11 months 6 days ago Sanofi's High-Dose Flu Vaccine Shows Enhanced Protection for Seniors Sanofi Flu Vaccine Senior Health Hospitalization Reduction FLUNITY-HD Study
BRIEF published on 10/20/2025 at 07:05, 11 months 6 days ago Le vaccin antigrippal à haute dose de Sanofi offre une protection renforcée aux personnes âgées Sanofi Vaccin Contre La Grippe Réduction Des Hospitalisations Santé Des Personnes Âgées Étude FLUNITY-HD
PRESS RELEASE published on 10/20/2025 at 07:00, 11 months 6 days ago Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les seniors par rapport aux vaccins à dose standard Efficacité Sanofi Seniors Hospitalisations Vaccin Antigrippal
PRESS RELEASE published on 10/20/2025 at 07:00, 11 months 6 days ago Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Sanofi's high-dose influenza vaccine Efluelda/Fluzone High-Dose shows superior protection for older adults by reducing hospitalizations. FLUNITY-HD study details robust evidence published in The Lancet Older Adults Sanofi Influenza Vaccine FLUNITY-HD Study Hospitalizations
Published on 09/26/2026 at 01:00, 1 day 4 hours ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 1 day 7 hours ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 1 day 12 hours ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 1 day 14 hours ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 15:30, 14 hours 1 minute ago QUORRA X5 fait ses débuts mondiaux à REHACARE International 2026 en Allemagne
Published on 09/26/2026 at 15:30, 14 hours 1 minute ago QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 14 hours 16 minutes ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 21 hours 46 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 1 day 5 hours ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 17:45, 1 day 11 hours ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 1 day 11 hours ago Availability of the 2026 half-year financial report